AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31474458 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline (450 mg orally every 24 h for 48 h then 300 mg orally every 24 h for 7-14 days)
Number of subjects: 735
Study 31474458 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 735
Study 31474458 — intervention group
Group type: COMPARATOR
Intervention: Linezolid (600 mg orally every 12 h for 7-14 days)
Number of subjects: 735
Study 31264623 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller range of stimulus onset asynchronies
Number of subjects: 51
Study 31264623 — intervention group
Group type: COMPARATOR
Intervention: Larger range of stimulus onset asynchronies
Number of subjects: 51
Study 27069426 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Technique (HT)
Number of subjects: 14
Study 27069426 — intervention group
Group type: COMPARATOR
Intervention: End Range Loading (ERL)
Number of subjects: 14
Study 24499441 — intervention group
Group type: COMPARATOR
Intervention: LET 2.5 mg/day
Number of subjects: 168
Study 24499441 — intervention group
Group type: EXPERIMENTAL
Intervention: LET 2.5 mg/day + ZOL 4 mg every 4 weeks (total of 7 infusions)
Number of subjects: 168
Study 21656079 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-event weeks following celebrity suicides
Number of subjects: 27605
Study 19745216 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg of hemagglutinin antigen by intramuscular injection
Number of subjects: 240
Study 19745216 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg of hemagglutinin antigen by intramuscular injection
Number of subjects: 240
Study 19745216 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg and 30 microg doses after the second dose
Number of subjects: 240
Study 19745216 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg and 30 microg doses
Number of subjects: 240
Study 17513662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck extension (5 mL of contrast injected)
Number of subjects: 42
Study 17513662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck flexion (5 mL of contrast injected)
Number of subjects: 42
Study 17513662 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral position (5 mL of contrast injected)
Number of subjects: 42
Study 14759294 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of buserelin
Number of subjects: 195
Study 14759294 — intervention group
Group type: EXPERIMENTAL
Intervention: s.c. administration of buserelin
Number of subjects: 195
Study 14759294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human menopausal gonadotrophin (HMG)
Number of subjects: 195
Study 14759294 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 195
Study 14759294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian stimulation with 225 IU per day of either HMG or rFSH
Number of subjects: 195
Study 11361157 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal estrogen-progestin replacement
Number of subjects: 0
Study 11361157 — intervention group
Group type: COMPARATOR
Intervention: Ongoing randomized clinical trials
Number of subjects: 0
Study 9571968 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR 600 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Number of subjects: 33
Study 9571968 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR 800 mg/body/day with radiotherapy and SPG (20 mg twice/week or 40 mg/week)
Number of subjects: 33
Study 9571968 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of radiotherapy, 5'-DFUR and SPG
Number of subjects: 33
Study 7917580 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg alendronate daily for 6 months
Number of subjects: 20
Study 7917580 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg alendronate daily for 6 months
Number of subjects: 20
Study 3046406 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch pollen extracts alone
Number of subjects: 53
Study 3046406 — intervention group
Group type: COMPARATOR
Intervention: Patient-tailored extracts of birch, alder, and hazel pollen
Number of subjects: 53
Study 31709734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (IVMP)
Number of subjects: 97
Study 31709734 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PLEX)
Number of subjects: 97
Study 31709734 — intervention group
Group type: EXPERIMENTAL
Intervention: IVMP followed by PLEX
Number of subjects: 97
Study 31709734 — intervention group
Group type: EXPERIMENTAL
Intervention: PLEX alone
Number of subjects: 97
Study 29578620 — intervention group
Group type: EXPERIMENTAL
Intervention: APCI settings derived from multivariate linear models for trolox
Number of subjects: 30
Study 29578620 — intervention group
Group type: EXPERIMENTAL
Intervention: APCI settings derived from multivariate linear models for BHT
Number of subjects: 30
Study 29578620 — intervention group
Group type: COMPARATOR
Intervention: APCI settings for tocochromanols
Number of subjects: 30
Study 27180680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy milk (2 or 4 servings, 473 and 946 ml)
Number of subjects: 11
Study 27180680 — intervention group
Group type: COMPARATOR
Intervention: Rice beverage (control)
Number of subjects: 11
Study 27180680 — intervention group
Group type: COMPARATOR
Intervention: Water (473 ml)
Number of subjects: 11
Study 25477459 — intervention group
Group type: EXPERIMENTAL
Intervention: Summer jobs program
Number of subjects: 1634
Study 23732465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosectom
Number of subjects: 48
Study 23732465 — intervention group
Group type: COMPARATOR
Intervention: Flush knife
Number of subjects: 48
Study 20157835 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Therapy (QoLT)
Number of subjects: 40
Study 20157835 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 40
Study 18374426 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task with 3 rewards
Number of subjects: 63
Study 18374426 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task with 5 rewards
Number of subjects: 63
Study 18374426 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task with 7 rewards
Number of subjects: 63
Study 18374426 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual task (all conditions)
Number of subjects: 63
Study 15480852 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (3 g/d)
Number of subjects: 16
Study 15480852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15480852 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (6.75 g/d)
Number of subjects: 16
Study 15480852 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine
Number of subjects: 16
Study 12005142 — intervention group
Group type: EXPERIMENTAL
Intervention: Astra Tech implants
Number of subjects: 66
Study 12005142 — intervention group
Group type: COMPARATOR
Intervention: Brånemark System implants
Number of subjects: 66
Study 12005142 — intervention group
Group type: EXPERIMENTAL
Intervention: Both systems
Number of subjects: 66
Study 10493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 1.5 g/d
Number of subjects: 149
Study 10493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 3.75 g/d
Number of subjects: 149
Study 10493319 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride 3.0 g/d
Number of subjects: 149
Study 10493319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 8725997 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg thrice weekly
Number of subjects: 19
Study 1782952 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium chloride (80 mmol.24 h‐1)
Number of subjects: 298
Study 1782952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 7261665 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg sulindac per day
Number of subjects: 32
Study 7261665 — intervention group
Group type: COMPARATOR
Intervention: 1200 mg ibuprofen per day
Number of subjects: 32
Study 30501541 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Counseling Exercise (TCE)
Number of subjects: 51
Study 27471899 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with anterior chamber maintainer (Group B)
Number of subjects: 78
Study 27471899 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy (Group A)
Number of subjects: 78
Study 25632091 — intervention group
Group type: COMPARATOR
Intervention: Expensive placebo (subcutaneous novel injectable dopamine agonist placebo)
Number of subjects: 12
Study 25632091 — intervention group
Group type: COMPARATOR
Intervention: Cheap placebo (subcutaneous novel injectable dopamine agonist placebo)
Number of subjects: 12
Study 25632091 — intervention group
Group type: COMPARATOR
Intervention: Cheap placebo
Number of subjects: 12
Study 25632091 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 12
Study 23617608 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS‐TBI
Number of subjects: 0
Study 21785002 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 16
Study 21785002 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 19592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (premeal insulin aspart)
Number of subjects: 100
Study 19592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 100
Study 19592632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 19592632 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and Repaglinide (in patients with IGT)
Number of subjects: 100
Study 15924593 — intervention group
Group type: EXPERIMENTAL
Intervention: On-demand esomeprazole 20 mg
Number of subjects: 2156
Study 15924593 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous esomeprazole 20 mg once-daily
Number of subjects: 2156
Study 15924593 — intervention group
Group type: COMPARATOR
Intervention: Continuous ranitidine 150 mg twice-daily
Number of subjects: 2156
Study 12765745 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone 100 mg/day
Number of subjects: 34
Study 12765745 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone 400 mg/day
Number of subjects: 34
Study 12765745 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (both doses)
Number of subjects: 34
Study 10665128 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk fermented by Lactobacillus casei (strain DN-114 001)
Number of subjects: 287
Study 10665128 — intervention group
Group type: COMPARATOR
Intervention: Jellied milk (control product)
Number of subjects: 287
Study 10163302 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based interventions
Number of subjects: 6000
Study 10163302 — intervention group
Group type: EXPERIMENTAL
Intervention: School-plus-family interventions
Number of subjects: 6000
Study 10163302 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 6000
Study 1888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 57
Study 1888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational Emotive Therapy (RET)
Number of subjects: 57
Study 1888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Confederate ratings of overt behavior on the SSIT
Number of subjects: 57
Study 1888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment effectiveness
Number of subjects: 57
Study 1888325 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse factors
Number of subjects: 57
Study 6864377 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 to 300 micrograms nebulized fenoterol
Number of subjects: 31
Study 6864377 — intervention group
Group type: COMPARATOR
Intervention: 0, 100, 300, and 1000 micrograms nebulized fenoterol
Number of subjects: 31
Study 6864377 — intervention group
Group type: EXPERIMENTAL
Intervention: 3, 10, 30, or 100 micrograms nebulized fenoterol
Number of subjects: 31
Study 6864377 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 to 1000 micrograms nebulized fenoterol
Number of subjects: 31
Study 6864377 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 and 3 hours after administration
Number of subjects: 31
Study 31068332 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held fan
Number of subjects: 41
Study 28701205 — intervention group
Group type: EXPERIMENTAL
Intervention: Art therapy
Number of subjects: 90
Study 28701205 — intervention group
Group type: EXPERIMENTAL
Intervention: Music reminiscence activity
Number of subjects: 90
Study 28701205 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 28701205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Art therapy and Music reminiscence)
Number of subjects: 90
Study 26463607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (5,000 U/kg intravenous injection before skin incision and at the end of operation)
Number of subjects: 48
Study 26463607 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Number of subjects: 48
Study 26463607 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 48
Study 22920723 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE) - 3 capsules/day for the first 12 weeks, then 6 capsules/day for the next 12 weeks
Number of subjects: 76
Study 22920723 — intervention group
Group type: COMPARATOR
Intervention: Toki-shakuyaku-san (TJ23) - control group, 24 weeks of open treatment
Number of subjects: 76
Study 22920723 — intervention group
Group type: EXPERIMENTAL
Intervention: Porcine placental extract (PPE)
Number of subjects: 76
Study 21718270 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity functional weight‐bearing exercise program
Number of subjects: 191
Study 21718270 — intervention group
Group type: COMPARATOR
Intervention: Control activity
Number of subjects: 191
Study 19139666 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion with allograft and plate
Number of subjects: 488
Study 17566395 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp expansion of the uterus using scissors
Number of subjects: 300
Study 17566395 — intervention group
Group type: COMPARATOR
Intervention: Blunt expansion of the uterus using surgeon's indexes
Number of subjects: 300
Study 15842594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation (meperidine 62.5 mg and midazolam 2.5 mg)
Number of subjects: 17
Study 15842594 — intervention group
Group type: COMPARATOR
Intervention: No Sedation
Number of subjects: 17
Study 12456070 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Cere) 30 ml infusion, five days/week for six weeks
Number of subjects: 0
Study 12456070 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion, five days/week for six weeks
Number of subjects: 0
Study 10397380 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 240
Study 10397380 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 240
Study 8759491 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold or methotrexate (MTX) therapy
Number of subjects: 11
Study 8759491 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 11
Study 1882158 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (specific antibiotics not mentioned)
Number of subjects: 21
Study 1882158 — intervention group
Group type: COMPARATOR
Intervention: Various antibiotics tested (specifics not mentioned)
Number of subjects: 21
Study 6415511 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 61
Study 6415511 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 61
Study 31468247 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental changes made by RCH staff to increase FV intake
Number of subjects: 614
Study 31468247 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-intervention mean servings of FV intake
Number of subjects: 614
Study 30526198 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 30526198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study 26747038 — intervention group
Group type: EXPERIMENTAL
Intervention: Bristol Girls Dance Project (BGDP) - a 20-week school-based intervention consisting of two 75 min after-school dance sessions per week.
Number of subjects: 571
Study 26747038 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 571
Study 25092393 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-mg fimasartan
Number of subjects: 293
Study 25092393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 293
Study 21816445 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program consisting of an unsupervised walking exercise for 4 months in NGT individuals.
Number of subjects: 112
Study 21816445 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine or palmitate exposure in cultured skeletal muscle.
Number of subjects: 112
Study 21816445 — intervention group
Group type: COMPARATOR
Intervention: T2DM patients (control group).
Number of subjects: 112
Study 20308769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group)
Number of subjects: 290
Study 20308769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group)
Number of subjects: 290
Study 20308769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol granules (60,000 IU) orally once in two months (two‐monthly D₃ group) in USES subjects
Number of subjects: 290
Study 20308769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol granules (60,000 IU) orally once a month (one‐monthly D₃ group) in USES subjects
Number of subjects: 290
Study 17046964 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg every other week)
Number of subjects: 313
Study 16286532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 129
Study 16286532 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 129
Study 12172406 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 721
Study 12172406 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 721
Study 12172406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study 10212791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy combined with radiotherapy
Number of subjects: 83
Study 10212791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy
Number of subjects: 83
Study 10212791 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 83
Study 7597118 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-LOW
Number of subjects: 41
Study 7597118 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-HIGH
Number of subjects: 41
Study 7597118 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO-LOW
Number of subjects: 41
Study 7597118 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO-HIGH
Number of subjects: 41
Study 2112877 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg recombinant tissue‐type plasminogen activator (rt‐PA) intravenously over 3 hours
Number of subjects: 721
Study 2112877 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 721
Study 306577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 123
Study 306577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ampicillin
Number of subjects: 123
Study 306577 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Number of subjects: 123
Study 306577 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonamide vaginal cream
Number of subjects: 123
Study 306577 — intervention group
Group type: COMPARATOR
Intervention: Persistent H. vaginalis infection
Number of subjects: 123
Study 306577 — intervention group
Group type: COMPARATOR
Intervention: No persistent H. vaginalis infection
Number of subjects: 123
Study 29253700 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation Training (ST) group
Number of subjects: 10
Study 29253700 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 27594381 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Bifidobacterium breve BBG-001 (6.7 × 10(7) to 6.7 × 10(9) CFU per dose)
Number of subjects: 1315
Study 27594381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 ml of one‐eighth‐strength infant formula Neocate)
Number of subjects: 1315
Study 24281852 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonoid intake
Number of subjects: 1778
Study 24281852 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical model
Number of subjects: 1778
Study 24384995 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU)
Number of subjects: 250
Study 24384995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 19484402 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral LLLT (n = 16)
Number of subjects: 48
Study 19484402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral LLLT (n = 16)
Number of subjects: 48
Study 19484402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 48
Study 18467115 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 44
Study 18467115 — intervention group
Group type: COMPARATOR
Intervention: Risedronate 5 mg/day (Control)
Number of subjects: 44
Study 15986863 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 10 g/day
Number of subjects: 86
Study 15986863 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed guar gum (PHGG) 5 g/day
Number of subjects: 86
Study 12841561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sauna-bathing allowed from 3rd postoperative day
Number of subjects: 79
Study 12841561 — intervention group
Group type: COMPARATOR
Intervention: Sauna-bathing prohibited until sutures were removed
Number of subjects: 79
Study 10526823 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 30